Studies no-reflow in heart attack patients given tirofiban into the heart artery
Tests tirofiban given into the heart artery in adults with STEMI heart attack.
Plain-language title generated from the registry record
Registry title: No-Reflow in Patients With STEMI After Intracoronary Tirofiban After Opening of the Track
Key facts
- Where
- Kafr ash Shaykh, EgyptSee the site
Where in Egypt
- Kafrelsheikh UniversityKafr ash Shaykh, EgyptTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Kafrelsheikh University
- Trial code
- NCT06966674
- Record updated
- 13 May 2025
- Original description
This study aims to assess the no-reflow in patients with STEMI after intracoronary glycoprotein IIb/IIIa inhibitors after opening of track in thrombus.Read full original descriptionShow less
Assessment of No-Reflow in Patients With STEMI After Intracoronary Tirofiban After Opening of the Track
This study aims to assess the no-reflow in patients with STEMI after intracoronary glycoprotein IIb/IIIa inhibitors after opening of track in thrombus.
Inclusion: Age ≥ 18 years old; Both sexes; Patients with STEMI. ST-segment elevated myocardial infarction is defined as typical chest pain >30 minutes with ST-segment elevation of >1 mm in at least 2 consecutive leads on the electrocardiogram or new-onset left bundle brunch block.
Exclusion: Treatment with thrombolytic drugs in the previous 24 hours; Known malignancy; End-stage liver disease; Renal failure with glomerular filtration<30 ml/min; Thrombocytopenia; Cardiogenic shock; Contraindication for the use of tirofiban.